Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

This publication has 60 references indexed in Scilit:

• [Ser2]- and [Ser(P)2]Incretin Analogs
  Journal of Biological Chemistry, 2004
• Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
  Critical Reviews in Clinical Laboratory Sciences, 2003
• Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
  Expert Opinion on Investigational Drugs, 2003
• Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
  Nature Structural & Molecular Biology, 2002
• A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells
  The FASEB Journal, 2002
• New drug targets for type 2 diabetes and the metabolic syndrome
  Nature, 2001
• Investigation of Glucose-dependent Insulinotropic Polypeptide(1-42) and Glucagon-like Peptide-1-(7-36) Degradation by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry
  Published by Elsevier ,1996
• Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients
  Diabetes Care, 1996
• Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
  European Journal of Biochemistry, 1993
• Gut hormones and diabetes mellitus
  Diabetes/Metabolism Research and Reviews, 1992